Paper39200065
Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae.
Wong DW. Antibiotics (Basel), 2024. Cited by 8 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae. Papers, record 39200065. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39200065
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37,982,631 | In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates. | Microbiol Spectr | 2023 | https://conductscience.org/library/papers/37982631 | PubMed |
| 2 | 31,802,119 | Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1. | Clin Infect Dis | 2020 | https://conductscience.org/library/papers/31802119 | PubMed |
| 3 | 35,439,291 | Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). | Clin Infect Dis | 2022 | https://conductscience.org/library/papers/35439291 | PubMed |
| 4 | 30,395,986 | In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). | Int J Antimicrob Agents | 2019 | https://conductscience.org/library/papers/30395986 | PubMed |
| 5 | 38,176,458 | Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance. | Int J Antimicrob Agents | 2024 | https://conductscience.org/library/papers/38176458 | PubMed |
| 6 | 28,167,541 | Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28167541 | PubMed |
| 7 | 26,850,824 | Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. | Clin Microbiol Infect | 2016 | https://conductscience.org/library/papers/26850824 | PubMed |
| 8 | 23,329,317 | Global spread of antibiotic resistance: the example of New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. | J Med Microbiol | 2013 | https://conductscience.org/library/papers/23329317 | PubMed |
| 9 | 35,811,669 | Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-Resistant Klebsiella pneumoniae With Decreased Susceptibility to Aztreonam/Avibactam in China. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/35811669 | PubMed |
| 10 | 38,156,518 | Comparison of ETEST® superposition method and the MTS™ Aztreonam-avibactam strip with the reference method for aztreonam/avibactam susceptibility testing. | J Antimicrob Chemother | 2024 | https://conductscience.org/library/papers/38156518 | PubMed |
| 11 | 31,722,380 | In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/31722380 | PubMed |
| 12 | 36,968,952 | Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019-21). | JAC Antimicrob Resist | 2023 | https://conductscience.org/library/papers/36968952 | PubMed |
| 13 | 31,704,216 | Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases. | Int J Antimicrob Agents | 2020 | https://conductscience.org/library/papers/31704216 | PubMed |
| 14 | 31,828,337 | Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. | J Antimicrob Chemother | 2020 | https://conductscience.org/library/papers/31828337 | PubMed |
| 15 | 37,154,758 | In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae. | Microbiol Spectr | 2023 | https://conductscience.org/library/papers/37154758 | PubMed |
| 16 | 36,225,496 | A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam. | Cureus | 2022 | https://conductscience.org/library/papers/36225496 | PubMed |
| 17 | 32,151,332 | Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. | Lancet Infect Dis | 2020 | https://conductscience.org/library/papers/32151332 | PubMed |
| 18 | 28,303,449 | Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy. | Drugs | 2017 | https://conductscience.org/library/papers/28303449 | PubMed |
| 19 | 34,424,044 | Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34424044 | PubMed |
| 20 | 38,252,170 | Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation. | Eur J Clin Pharmacol | 2024 | https://conductscience.org/library/papers/38252170 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,670,646 | Achromobacter species in cystic fibrosis and chronic lung disease: a review of virulence, antibiotic resistance, diagnostic challenges, and emerging therapies. | Ther Adv Respir Dis | 2026 | https://conductscience.org/library/papers/42670646 | PubMed |
| 42,311,930 | Clinical Characteristics, Antimicrobial Resistance Profiles and Carbapenemases Genotypes of Providencia rettgeri: A 5-Year Retrospective Study in a Tertiary Teaching Hospital in Northern China. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42311930 | PubMed |
| 42,192,725 | Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42192725 | PubMed |
| 42,191,848 | Aztreonam-avibactam at the frontline: A dual-agent approach to metallo-β-lactamase resistance. | J Antibiot (Tokyo) | 2026 | https://conductscience.org/library/papers/42191848 | PubMed |
| 41,892,432 | Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41892432 | PubMed |
| 41,705,828 | In vitro activity of aztreonam-avibactam and distribution of carbapenemase genes in ceftazidime-avibactam-resistant carbapenem-resistant Enterobacterales: data from the global Antimicrobial Testing Leadership and Surveillance, 2019-2023. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/41705828 | PubMed |
| 41,630,025 | Genomic epidemiology and aztreonam-avibactam resistance mechanisms of Proteus mirabilis in china: an eight-year retrospective study. | Ann Clin Microbiol Antimicrob | 2026 | https://conductscience.org/library/papers/41630025 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MBL3P | 50,639 | PubTator's text mining | https://conductscience.org/library/genes/50639 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39200065
GET https://conductscience.org/api/papers/v1/39200065/references?page=2